Friday, April 15, 2016
In line with its commitment to help address the world’s most pressing health care issues, and improve and save more lives, Ethicon, a medical device company of the Johnson & Johnson family of companies, today announced the completion of its acquisition of NeuWave Medical, Inc., a privately held medical device company that manufactures and markets minimally invasive soft-tissue microwave ablation systems. This acquisition is consistent with the Johnson & Johnson Medical Devices’ strategy of advancing innovation and investing in areas of unmet medical needs such as surgical oncology.
“Currently, there are limited treatment options for soft-tissue, non-resectable lesions,” said Michael del Prado, Company Group Chairman of Ethicon. “Together with NeuWave Medical, Ethicon can bring minimally invasive treatment options to make a difference for patients around the world. This is especially important for patients who may not be medically eligible for traditional surgery. We can now offer physicians and patients more choice in treatment options for soft-tissue lesions.”
NeuWave Medical’s products are currently used by physicians in over half of the top cancer centers in the United States. NeuWave Medical’s Certus® 140 ablation system’s high-powered computer and intuitive touchscreen interface enables activation of single or simultaneous multiple probe procedures for patients with soft-tissue lesions. This allows physicians to effectively tailor ablations for lesions of varying shapes and sizes. NeuWave Medical’s probe family includes conventional probes and the only Precision™ PR probe to limit the ablation length, allowing precise and controlled ablations.
“NeuWave Medical’s unique ablation technology was originally developed by physicians and microwave scientists from the University of Wisconsin to maximize energy delivery to tissue, minimize invasiveness and provide physician-friendly workflow,” said Dan Sullivan, the CEO and President of NeuWave Medical. “This acquisition now provides NeuWave Medical with the ability to accelerate our innovation pipeline and expand the global footprint of our unique technologies, while allowing Ethicon to reach new patients by expanding the availability of a novel intervention that goes beyond surgical options in wide use today.”
Financial terms of the transaction have not been disclosed.
Source : ethicon.com
